Also known as: Tremfya
Guselkumab is a fully human monoclonal antibody that selectively inhibits interleukin-23 (IL-23), indicated for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. Mediocon Inc supplies pharmaceutical-grade Guselkumab API.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Assay | ≥98.0% (as per pharmacopoeia) |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Residue on Ignition | NMT 0.1% |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Packing | 25 kg HDPE drums / as per requirement |